19 Nov 2026, 08:16
Company UpdateMS
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 19 Nov 2026, 08:16 | Encouraging Disease-Free Survival in Phase II Sarcoma Trial | Company Update | MS | 11001 | |
| 18 Nov 2026, 09:25 | Immutep Investor Update | Periodic Reports | — | 03014 | |
| 11 Nov 2026, 09:17 | Immutep Expands US Patents for Efti Combination Therapies | Company Update | — | 11001 | |
| 11 Nov 2026, 09:06 | EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract | Company Update | — | 11001 | |
| 9 Nov 2026, 08:29 | IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition | Company Update | MS | 11001 | |
| 5 Nov 2026, 08:24 | Upcoming Poster Presentations at CTOS and ESMO IO 2026 | Company Administration | — | 12008 | |
| 29 Oct 2026, 08:04 | Immutep Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19001, 19006 | |
| 28 Oct 2026, 11:11 | Immutep Receives A$2.16 million French R&D Tax Incentive | Periodic Reports | MS | 03014, 12008 | |
| 27 Oct 2026, 13:41 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 27 Oct 2026, 13:35 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 27 Oct 2026, 13:28 | Annual Report to shareholders | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 26 Oct 2026, 08:24 | Annual Report filed on Form 20-F | Financial Results | — | 03001, 03002, 03011, 03013, 03020 | |
| 23 Oct 2026, 17:01 | Quality of Life Data from EFTISARC-NEO presented at ESMO | Company Update | — | 11001 | |
| 19 Oct 2026, 08:10 | Late-Breaking Abstract on IMP761 to be presented at ACR 2026 | Company Update | — | 11001 | |
| 15 Oct 2026, 09:19 | 2026 Annual General Meeting and Key Dates | Meetings & Governance | — | 08006 | |
| 14 Oct 2026, 09:14 | Immutep & Monash Secure Further ARC Funding for LAG-3 | Company Update | — | 11001 | |
| 13 Oct 2026, 11:51 | Immutep Regains Compliance with Nasdaq | Company Administration | — | 12008 | |
| 9 Oct 2026, 16:51 | Audit and Risk Committee Update | Company Administration | — | 12008 | |
| 5 Oct 2026, 09:50 | Final Director's Interest Notice - P Meyers | Director Interests | — | 02010 | |
| 5 Oct 2026, 09:44 | Notification of cessation of securities - IMM | Securities Administration | — | 06027 | |
| 5 Oct 2026, 09:37 | Resignation of Non-Executive Director | Company Administration | — | 12001 | |
| 1 Oct 2026, 08:16 | Change of Director's Interest Notice - P Meyers | Director Interests | — | 02009 | |
| 1 Oct 2026, 08:15 | Application for quotation of securities - IMM | Securities Administration | — | 06020 | |
| 30 Sept 2026, 09:25 | Immutep receives Australian R&D Tax Incentive | Periodic Reports | — | 03014 | |
| 21 Sept 2026, 12:39 | Change to American Depositary Share Ratio | Company Administration | — | 06009, 12008 | |
| 11 Sept 2026, 09:01 | Immutep Outlines Focused Development Strategy for Efti | Company Update | MS | 11001 | |
| 4 Sept 2026, 17:10 | S&P DJI Announces September 2026 Quarterly Rebalance | Other | MS | — | |
| 31 Aug 2026, 09:12 | Appendix 4E & 2026 Full Year Statutory Accounts | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 20 Aug 2026, 07:58 | Immutep Corporate Presentation | Presentations | — | 03026 | |
| 30 July 2026, 08:24 | Immutep Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 24 July 2026, 09:01 | Abstract Accepted for Presentation at ESMO Congress 2026 | Company Administration | — | 12008 | |
| 14 July 2026, 12:11 | Fourth U.S. Patent Secured for Efti and PD-1 Combination | Company Update | — | 11001 | |
| 13 July 2026, 09:38 | TACTI-004 Update & Positive Mature Data from INSIGHT-003 | Company Update | MS | 11001 | |
| 1 July 2026, 08:14 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 17 June 2026, 08:22 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 16 June 2026, 08:16 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 15 June 2026, 08:19 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 10 June 2026, 08:19 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 9 June 2026, 17:58 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 9 June 2026, 08:13 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 9 June 2026, 08:12 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 4 June 2026, 17:30 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 4 June 2026, 08:23 | Immutep Presents Positive IMP761 Phase I Data at EULAR 2026 | Company Update | — | 11001 | |
| 29 May 2026, 17:03 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 28 May 2026, 09:18 | Efti immune activation associated with improved survival | Company Update | — | 11001 | |
| 27 May 2026, 18:51 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 11 May 2026, 08:16 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 30 Apr 2026, 09:21 | Immutep Receives Nasdaq Notice of Bid Price Deficiency | Company Administration | — | 12008 | |
| 30 Apr 2026, 09:01 | Immutep Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 27 Apr 2026, 08:15 | Change in substantial holding | Substantial Holders | — | 02002 |